Skip to Content

Limbitrol (amitriptyline / chlordiazepoxide) and Alcohol / Food Interactions

There are 2 alcohol/food/lifestyle interactions with Limbitrol (amitriptyline / chlordiazepoxide) which include:

Moderate

chlordiazePOXIDE ↔ food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
  2. "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.
  3. "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.
  4. Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):
View all 4 references
Moderate

Obesity

Moderate Potential Hazard, Moderate plausibility

benzodiazepines - obesity

The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat. Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam. Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status. Longer dosing intervals may be appropriate. When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.

References

  1. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical, Abbott Park, IL.
  2. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories, Nutley, NJ.
  3. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  5. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  6. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
  7. "Product Information. Klonopin (clonazepam)." Roche Laboratories, Nutley, NJ.
  8. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.
  9. "Product Information. ProSom (estazolam)." Abbott Pharmaceutical, Abbott Park, IL.
  10. "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.
  11. "Product Information. Doral (quazepam)." Wallace Laboratories, Cranbury, NJ.
  12. "Product Information. Dalmane (flurazepam)." Roche Laboratories, Nutley, NJ.
  13. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
  14. "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.
View all 14 references

Limbitrol (amitriptyline / chlordiazepoxide) drug Interactions

There are 1260 drug interactions with Limbitrol (amitriptyline / chlordiazepoxide)

Limbitrol (amitriptyline / chlordiazepoxide) disease Interactions

There are 32 disease interactions with Limbitrol (amitriptyline / chlordiazepoxide) which include:

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide